SNNAQ (Sienna Biopharmaceuticals) Operating Income: $-53.78 Mil (TTM As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sienna Biopharmaceuticals Operating Income?

Sienna Biopharmaceuticals SNNAQ -99.00% Operating Income is $-53.78 Mil as of Sep. 2019.

Sienna Biopharmaceuticals's Operating Income for the three months ended in Sep. 2019 was $-8.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2019 was $-53.78 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Sienna Biopharmaceuticals's Operating Income for the three months ended in Sep. 2019 was $-8.84 Mil. Sienna Biopharmaceuticals's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. Therefore, Sienna Biopharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2019 was %.

Sienna Biopharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sienna Biopharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2019 was -32.06%. Sienna Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -850.40%.

Sienna Biopharmaceuticals  (OTCPK:SNNAQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sienna Biopharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

ROC % (Q: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 ))/ count )
=-35.364 * ( 1 - 53.77% )/( (71.108 + 30.868)/ 2 )
=-16.3487772/50.988
=-32.06 %

where

Invested Capital(Q: Jun. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=107.625 - 6.713 - ( 49.207 - max(0, 20.813 - 50.617+49.207))
=71.108

Invested Capital(Q: Sep. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=43.492 - 1.292 - ( 11.332 - max(0, 1.292 - 19.731+11.332))
=30.868

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Sienna Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2019 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2019  Q: Sep. 2019
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-35.364/( ( (0.949 + max(-19.403, 0)) + (0.261 + max(7.107, 0)) )/ 2 )
=-35.364/( ( 0.949 + 7.368 )/ 2 )
=-35.364/4.1585
=-850.40 %

where Working Capital is:

Working Capital(Q: Jun. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.41) - (6.713 + 0 + 14.1)
=-19.403

Working Capital(Q: Sep. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 8.399) - (1.292 + 0 + 0)
=7.107

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Sienna Biopharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2019 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=-8.841/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Sienna Biopharmaceuticals Operating Income Related Terms

Sienna Biopharmaceuticals Operating Income Historical Data

* Premium members only.

The historical data trend for Sienna Biopharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sienna Biopharmaceuticals Operating Income Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
Operating Income
-11.11 -20.69 -48.57 -76.50

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.28 -21.37 -15.84 -7.73 -8.84

Sienna Biopharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-53.78 Mil mean?
Sienna Biopharmaceuticals (SNNAQ) has a Operating Income of $-53.78 Mil as of Sep. 2019. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Sienna Biopharmaceuticals and its competitors.
Is Sienna Biopharmaceuticals' Operating Income too high?
Sienna Biopharmaceuticals' current Operating Income is $-53.78 Mil.
How does Sienna Biopharmaceuticals' Operating Income compare to GTHR and PPCB?
Sienna Biopharmaceuticals' Operating Income of $-53.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Sienna Biopharmaceuticals and its competitors. Sienna Biopharmaceuticals's current Operating Income is $-53.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sienna Biopharmaceuticals stock overvalued right now?
Sienna Biopharmaceuticals (SNNAQ) has a current Operating Income of $-53.78 Mil. The current Operating Income is $-53.78 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Sienna Biopharmaceuticals (SNNAQ), the current Operating Income is $-53.78 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sienna Biopharmaceuticals Business Description

Address 30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.